SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending as its dedicated community celebrates its two-year anniversary on the Solana blockchain, driving conversation around the iconic "Whats UpDog?" meme and maintaining a bullish "The Dog Stays Up" sentiment with calls to accumulate.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as the community eagerly awaits imminent Phase 3 REGAL trial results, fueling strong conviction around GPS immunotherapy's potential for "curative" outcomes in AML. Investors are overwhelmingly bullish, dismissing persistent bearish takes from some while anticipating a significant short squeeze and potential for substantial buyout offers for its promising pipeline.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is rallying as market sentiment interprets recent statements on the Mideast conflict as a sign of de-escalation, sparking a 'Trump pump' and optimistic price targets among bulls, while skeptics warn of market manipulation, rising oil prices, and continued geopolitical uncertainty.

Aventus Network

Aventus Network ($AVT) is generating significant community interest following the formal incorporation of its DAO in the UAE and the appointment of a strategic advisor to bolster its regional presence. Traders are actively discussing its potential for a major breakout, emphasizing its enterprise-grade technology, Polkadot integration, and current low market capitalization as indicators of an undervalued asset.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending with high anticipation for its R2 launch event, propelled by a recent analyst upgrade and the strong performance of its software division, as the community actively debates the stock's future potential amid rising energy costs boosting EV adoption.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is a hot topic after its recent earnings showed a beat on Q4 results but presented a cautious outlook for the coming fiscal year, fueling mixed sentiment. While many in the community are debating short squeeze potential and highlighting the company's substantial real estate assets, others are concerned about soft sales trends and the broader challenging retail landscape.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its robust oncology pipeline delivers significant news, including positive Phase 3 data for a breast cancer drug and promising lung cancer therapy results, which has garnered a Goldman Sachs upgrade and shifted community focus towards its potential beyond COVID-19 vaccines.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is actively discussed following its proposed convertible senior notes offering, which raises community questions about management's strategy amid persistent buyout rumors and growing optimism for Casgevy's commercial ramp-up and positive early data from its zugo-cel program, including a new Eli Lilly partnership.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing intense community debate ahead of its earnings report, as investors weigh significant debt-fueled AI infrastructure spending and recent layoff rumors against its cloud growth potential, further complicated by conflicting reports surrounding a major OpenAI data center project.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending due to its aggressive investments in U.S. connectivity, fiber, and AI infrastructure, coupled with a strong earnings report, positive long-term outlook, and a substantial share buyback program. The community is actively debating whether these strategic moves position it as a compelling value and dividend play, despite ongoing competitive pressures in the telecom sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on...

Agenus (AGEN) to Release Earnings on Tuesday

Agenus (NASDAQ:AGEN) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have been assigned an average rating of "Hold" from the five research firms that are covering the company, Marketbeat reports. One investment...

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an...

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted...

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has earned an average recommendation of "Hold" from the five analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has...

Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch

Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a...

Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to...

Agenus to Host First 2026 Stakeholder Webcast

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus Global Momentum Entering 2026 on...

Agenus Inc. (NASDAQ:AGEN) Sees Significant Increase in Short Interest

Agenus Inc. (NASDAQ:AGEN - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totaling 3,399,217 shares, an increase of...

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AGEN News

AGENAgenus Inc